Ventricular Tachycardia - Pipeline Review, H1 2020

Ventricular Tachycardia - Pipeline Review, H1 2020



latest Pharmaceutical and Healthcare disease pipeline guide Ventricular Tachycardia - Pipeline Review, H1 2020, provides an overview of the Ventricular Tachycardia (Cardiovascular) pipeline landscape.

Ventricular tachycardia is a very fast heart rhythm that begins in the ventricles. Symptoms of ventricular tachycardia include dizziness, fainting, fatigue, chest pain and shortness of breath. Causes include cardiomyopathy, ischemic heart disease and heart failure. Risk factors include age, family history and medical history. Treatment includes antiarrhythmic medication.

Report Highlights

Pharmaceutical and Healthcare latest pipeline guide Ventricular Tachycardia - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Ventricular Tachycardia (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ventricular Tachycardia (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Ventricular Tachycardia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 1, 5 and 3 respectively.

Ventricular Tachycardia (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Ventricular Tachycardia (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Ventricular Tachycardia (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Ventricular Tachycardia (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Ventricular Tachycardia (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Ventricular Tachycardia (Cardiovascular)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Ventricular Tachycardia (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Ventricular Tachycardia (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Ventricular Tachycardia - Overview
Ventricular Tachycardia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Ventricular Tachycardia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Ventricular Tachycardia - Companies Involved in Therapeutics Development
Academic Pharmaceuticals Inc
Armgo Pharma Inc
BioStem Technologies Inc
Elex Biotech LLC
Espero BioPharma Inc
GEXVal Inc
Gilead Sciences Inc
InCarda Therapeutics Inc
Milestone Pharmaceuticals Inc
Vivasc Therapeutics Inc
Ventricular Tachycardia - Drug Profiles
amiodarone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BSEM-125 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
budiodarone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
etripamil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
flecainide acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GS-967 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Cardiomyopathies and Catecholaminergic Polymorphic Ventricular Tachycardia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize Ryanodine Receptor 2 for Catecholaminergic Polymorphic Ventricular Tachycardia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit FKBP1A for Cardiovascular Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
soestelol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Ventricular Tachycardia - Dormant Projects
Ventricular Tachycardia - Discontinued Products
Ventricular Tachycardia - Product Development Milestones
Featured News & Press Releases
Mar 23, 2020: Milestone Pharmaceuticals announces topline results from first-of-its-kind phase 3 NODE-301 trial of etripamil for at-home acute PSVT treatment
Oct 03, 2019: Milestone Pharmaceuticals announces first patient enrolled in NODE-303 open-label safety study of Etripamil in PSVT
May 21, 2019: Milestone Pharmaceuticals presents studies on the economic impacts of PSVT at the ISPOR 2019 Annual Meeting
Apr 16, 2019: Milestone Pharmaceuticals appoints Paul Edick chairman of its board of directors
Apr 16, 2019: Milestone Pharmaceuticals appoints Paul Edick chairman of its board of directors
Aug 08, 2018: Milestone Pharmaceuticals announces first patient randomized in the phase 3 NODE-301 clinical trial evaluating Etripamil for termination of paroxysmal supraventricular tachycardia (PSVT) episodes
May 11, 2017: Milestone Pharmaceuticals Announces Etripamil Phase 2 Clinical Program Success for the Treatment of Paroxysmal Supraventricular Tachycardia
Apr 12, 2017: Milestone Pharmaceuticals to Present Etripamil Phase 2 Data at the Heart Rhythm Societys 38th Annual Scientific Sessions
Mar 07, 2017: Milestone Pharmaceuticals Announces Appointment of Joseph G. Oliveto as Chief Executive Officer
Aug 31, 2016: InCarda Therapeutics Initiates Enrollment of Phase 1 Clinical Trial of Inhaled Flecainide for the Treatment of Cardiac Arrhythmias
Jan 25, 2016: Milestone Pharmaceuticals Announces USAN Approval of Generic Name "Etripamil" for its Phase 2 Clinical Development Product for the Treatment of Paroxysmal Supraventricular Tachycardia
Jan 12, 2015: Milestone Pharmaceuticals Receives FDA Clearance of MSP-2017 Phase 2 IND
Nov 24, 2014: Milestone Announces Positive Phase 1 Data for MSP-2017; Supports Advancement into Phase 2 in PSVT Patients
Oct 28, 2013: Milestone Pharmaceuticals Initiates a Phase 1 Clinical Trial with MSP-2017
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables


Number of Products under Development for Ventricular Tachycardia, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Ventricular Tachycardia - Pipeline by Academic Pharmaceuticals Inc, H1 2020
Ventricular Tachycardia - Pipeline by Armgo Pharma Inc, H1 2020
Ventricular Tachycardia - Pipeline by BioStem Technologies Inc, H1 2020
Ventricular Tachycardia - Pipeline by Elex Biotech LLC, H1 2020
Ventricular Tachycardia - Pipeline by Espero BioPharma Inc, H1 2020
Ventricular Tachycardia - Pipeline by GEXVal Inc, H1 2020
Ventricular Tachycardia - Pipeline by Gilead Sciences Inc, H1 2020
Ventricular Tachycardia - Pipeline by InCarda Therapeutics Inc, H1 2020
Ventricular Tachycardia - Pipeline by Milestone Pharmaceuticals Inc, H1 2020
Ventricular Tachycardia - Pipeline by Vivasc Therapeutics Inc, H1 2020
Ventricular Tachycardia - Dormant Projects, H1 2020
Ventricular Tachycardia - Discontinued Products, H1 2020

List Of Figures


Number of Products under Development for Ventricular Tachycardia, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020

Ventricular Tachycardia (V-tach or VT) - Market Insight, Epidemiology and Market Forecast - 2030

Ventricular Tachycardia (V-tach or VT) - Market Insights, Epidemiology, and Market Forecast-2030 report delivers an in-depth understanding of the Ventricular Tachycardia (V-tach or VT) , historical and forecasted epidemiology

USD 6950 View Report

Ventricular Tachycardia - Pipeline Review, H1 2020

Ventricular Tachycardia - Pipeline Review, H1 2020 latest Pharmaceutical and Healthcare disease pipeline guide Ventricular Tachycardia - Pipeline Review, H1 2020, provides an overview of the Ventricular Tachycardia (Cardiovascular) pipeline

USD 2000 View Report

Ventricular Tachycardia (V-tach or VT) - Market Insight, Epidemiology and Market Forecast - 2030

Ventricular Tachycardia (V-tach or VT) - Market Insights, Epidemiology, and Market Forecast-2030 report delivers an in-depth understanding of the Ventricular Tachycardia (V-tach or VT) , historical and forecasted epidemiology

USD 6950 View Report

Ventricular Tachycardia - Pipeline Review, H2 2019

Ventricular Tachycardia - Pipeline Review, H2 2019latest Pharmaceutical and Healthcare disease pipeline guide Ventricular Tachycardia - Pipeline Review, H2 2019, provides an overview of the Ventricular Tachycardia (Cardiovascular) pipeline landscape.Ventricular

USD 2000 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available